Difference between revisions of "Non-small cell lung cancer, KRAS-mutated"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "][" to "] [") |
||
Line 4: | Line 4: | ||
|- | |- | ||
| style="background-color:#F0F0F0; width:15%" |[[File:Amit_Kulkarni.jpg|frameless|upright=0.3|center]] | | style="background-color:#F0F0F0; width:15%" |[[File:Amit_Kulkarni.jpg|frameless|upright=0.3|center]] | ||
− | | style="width:35%" |<big>[[User:Akulkarni|Amit Kulkarni, MBBS]]<br>University of Minnesota<br>Minneapolis, MN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/AmitKulkarniMD AmitKulkarniMD] | + | | style="width:35%" |<big>[[User:Akulkarni|Amit Kulkarni, MBBS]]<br>University of Minnesota<br>Minneapolis, MN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/AmitKulkarniMD AmitKulkarniMD] |
|style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.3|center]] | ||
− | |<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] | + | |<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] |
|- | |- | ||
|} | |} |
Revision as of 17:32, 12 October 2020
Page editor | Section editor | ||
---|---|---|---|
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN AmitKulkarniMD |
Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Advanced or metastatic disease, subsequent lines of therapy
Docetaxel monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Blumenschein et al. 2015 (GSK 114653) | 2011-2012 | Randomized Phase II (C) | Trametinib | Did not meet primary endpoint of PFS |
Jänne et al. 2017 (SELECT-1) | 2013-2016 | Phase III (C) | Docetaxel & Selumetinib | Did not meet primary endpoint of PFS |
Chemotherapy
- Docetaxel (Taxotere) 75 mg/m2 IV over 60 minutes once on day 1
Supportive medications
- Per JMEI: Dexamethasone (Decadron) 8 mg PO twice per day on days -1 to 2 (3 days)
- Per Chem et al. 2006: Dexamethasone (Decadron) as follows:
- 8 mg PO once per day on days 1, 8, 15; 12 hours prior to Docetaxel (Taxotere)
- 10 mg IV once per day on days 1, 8, 15; 30 minutes prior to Docetaxel (Taxotere)
- 8 mg PO once per day on days 1, 8, 15; 12 hours after Docetaxel (Taxotere)
21-day cycles
References
- GSK 114653: Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2015 May;26(5):894-901. Epub 2015 Feb 26. link to original article link to PMC article contains verified protocol PubMed NCT01362296
- SELECT-1: Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial. JAMA. 2017 May 9;317(18):1844-1853. link to original article contains verified protocol link to PMC article PubMed NCT01933932